June 29, 2017
Trump Administration Proposes Revisions To Nursing Home Protection Clause
The Trump Administration has proposed a revision to recent nursing home legislation, which delivered increased protections to nursing home residents. The revision would affect the forced arbitration clauses in extended care nursing home facilities.
The revision would alter the clause, which prohibits allocating federal funds to any nursing homes that mandates forced financial arbitration agreements with residents. Advocacy groups have fought against the revision, arguing that it would reduce protections for nursing home patients.
Vaginal Mesh Advocacy Grows With Lawsuits Against Device Complications In Australia
Women’s advocates fighting the side effects of vaginal mesh are gaining clout in Australia. Though the Royal Australian and the college of gynaecologists and obstetricians have continued to support and implement vaginal mesh to treat stress urinary incontinence and pelvic organ prolapse, lawsuits focusing on complications related to the device are growing.
Vaginal mesh can cause serious complications, including severe pelvic pain, mesh erosion and organ perforation. The Australian Pelvic Mesh Support Group has worked to raise awareness about the complications in an attempt to alter traditional perspectives. Next month, a large class action lawsuit including 450 women injured by vaginal mesh kicks off to assist affected patients seeking relief.
Eliquis Recalled Due To Improper Dosage Administered During Production
Bottles of Eliquis, a popular blood thinner, have been recalled by the pharmaceutical manufacturer Bristol-Myers Squibb. Also known as apixaban, Eliquis is used to prevent blood clots from reaching the lungs.
Certain bottles of Eliquis have 2.5mg tablets, instead of the intended dosage of 5 mg. The call includes 60-count bottles, labeled Lot# HN0063, with an expiration date of September 2019. If a patient does not receive the right dose, it could increase the risk of stroke, deep vein thrombosis (DVT) or pulmonary embolism (PE).
Essure Study Shows Device Removal Can Reduce Pain and Other Symptoms
A recent study of Essure, a controversial birth control device, examined if device removal would reduce complications like pain, cramping, irregular periods and more. The study was published in May and conducted by physicians in Department of Obstetrics and Gynecology at Brigham and Women’s Hospital in Boston, Massachusetts.
Researchers examined fifty-two women who underwent laparoscopic or hysteroscopic Essure removal between 2012 and 2016.
- 75% of women reported improvement in quality of life
- 56.3% of women reported improvement in sex life
- 53.1% of women reported improvement in pelvic pain
- 65.6% of women reported improvement in daily activities
- 87.5% of women reported improvement in al areas
- 31.3% of women reported ongoing or worsened symptoms
The Researchers concluded that removal of Essure “may be effective for treating most women with symptoms attributed to the device.” In the conclusion, the researchers added that “some symptoms may persist or even worsen following surgery.”
More than 1,1000 Taxotere Lawsuits Have Been Filed in New Orleans
Since Oct. 2016, more than 1,000 lawsuits for Taxotere side effects have been filed in New Orleans, Louisiana. The individuals have filed against Sanofi-Aventis, the maker of a chemotherapy treatment. that causes a permanent form of alopecia hair loss.
Taxotere treatments can cause alopecia, a permanent form of hair loss that is particularly devastating for cancer patients who are fighting or who have just overcome cancer. The cases are part of a pending multidistrict litigation, In Re: Taxotere (Docetaxel) Products Liability Litigation, that continues to grow.